Please login to the form below
SAR302503
This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.
Jakafi cleared for bone marrow disorder by FDA
pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Latest news
-
Sanofi pulls development of blood cancer drug
The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
-
Jakavi shows long-term survival benefit in myelofibrosis
Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
-
Sanofi plans to file JAK2 inhibitor after positive phase III
Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera
-
Sanofi has 65 new compounds in development, says R&D chief
Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed
-
Gilead expands in cancer with $510m YM BioSciences deal
Aside from Jakafi, other JAK inhibitors being developed for myelofibrosis include Sanofi's selective JAK2 inhibitor SAR302503 - phase II data for which were presented at ASH - and Cell Therapeutics Inc's
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2013
While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Huntsworth buys Giant Creative Strategy
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
- Brexit rebels win vote on European Medicines Agency alignment
- Data Visualisation
- The True Potential of Mobile Health Tech
- NHS England to Vertex: come clean on Orkambi offer
PMHub
WCG
WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
